Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Faron Pharmaceuticals Oy ( (GB:FARN) ) has issued an announcement.
Faron Pharmaceuticals announced that its Non-Executive Chairman, Tuomo Pätsi, acquired 21,500 ordinary shares in the company, increasing his total holdings to 53,265 shares, which represents 0.05% of the voting rights. This transaction reflects potential confidence in the company’s future, possibly impacting investor perception and stakeholder interests.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel immunotherapies to tackle cancers. The company’s lead asset is bexmarilimab, an investigational immunotherapy designed to overcome resistance to existing treatments by targeting myeloid cell function and reprogramming the immune system.
See more insights into FARN stock on TipRanks’ Stock Analysis page.